Investor Presentaiton
Successful
screening requires
both adherence
and performance
120M
Avg Risk Individuals
Ages 45 - 851
Adherence
Colonoscopy
FIT
Cologuard
38% 2
43% 3
65%4
70M
Screened
Individuals 5
INVESTOR 20
DAY 23
50M
Unscreened
Individuals5
X
GUARDANT™
1. AACR Study, Cancer Prev Res (2020) 13 2. Singal AG, Gupta S, Skinner CS, et al. Effect of Colonoscopy Outreach vs Fecal Immunochemical Test Outreach
on Colorectal Cancer Screening Completion: A Randomized Clinical Trial. JAMA. 2017;318(9):806-815. doi:10.1001/jama.2017.11389 3. Cancer Prevention
Research. Impact of Patient Adherence to Stool-Based Colorectal Cancer Screening and Colonoscopy Following a Positive Test on Clinical
Outcomes, https://aacrjournals.org/cancerprevention research/article/14/9/845/666815/Impact-of-Patient-Adherence-to-Stool-Based
[aacrjournals.org.. ACS Colorectal Cancer Facts 2020-2022, 4. EXACT Sciences presentation at Goldman Sachs 44th Annual Global Healthcare Conference,
June 2023 5. ACS Colorectal Cancer Facts 2020-2022
114View entire presentation